[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20011192L - Ranolazinpreparater med depotvirkning - Google Patents

Ranolazinpreparater med depotvirkning

Info

Publication number
NO20011192L
NO20011192L NO20011192A NO20011192A NO20011192L NO 20011192 L NO20011192 L NO 20011192L NO 20011192 A NO20011192 A NO 20011192A NO 20011192 A NO20011192 A NO 20011192A NO 20011192 L NO20011192 L NO 20011192L
Authority
NO
Norway
Prior art keywords
ranolazine
preparations
depot effect
depot
effect
Prior art date
Application number
NO20011192A
Other languages
English (en)
Other versions
NO20011192D0 (no
NO320986B1 (no
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011192(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20011192D0 publication Critical patent/NO20011192D0/no
Publication of NO20011192L publication Critical patent/NO20011192L/no
Publication of NO320986B1 publication Critical patent/NO320986B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO20011192A 1998-09-10 2001-03-08 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning NO320986B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020968 WO2000013687A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (3)

Publication Number Publication Date
NO20011192D0 NO20011192D0 (no) 2001-03-08
NO20011192L true NO20011192L (no) 2001-04-30
NO320986B1 NO320986B1 (no) 2006-02-20

Family

ID=26796494

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20011191A NO319434B1 (no) 1998-09-10 2001-03-08 Farmasoytisk oral doseform av ranolazin-preparater med depotvirkning og en komprimert tablett.
NO20011192A NO320986B1 (no) 1998-09-10 2001-03-08 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO20054324A NO20054324L (no) 1998-09-10 2005-09-20 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO2009005C NO2009005I1 (no) 1998-09-10 2009-03-05 Ranolazin samt salter og solvater derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20011191A NO319434B1 (no) 1998-09-10 2001-03-08 Farmasoytisk oral doseform av ranolazin-preparater med depotvirkning og en komprimert tablett.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20054324A NO20054324L (no) 1998-09-10 2005-09-20 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO2009005C NO2009005I1 (no) 1998-09-10 2009-03-05 Ranolazin samt salter og solvater derav

Country Status (33)

Country Link
US (14) US6303607B1 (no)
EP (3) EP1527779A1 (no)
JP (2) JP3745621B2 (no)
KR (1) KR100475759B1 (no)
CN (2) CN1193757C (no)
AR (3) AR022085A1 (no)
AT (2) ATE285774T1 (no)
AU (4) AU760435B2 (no)
BR (2) BR9913626A (no)
CA (2) CA2342390C (no)
CY (1) CY2008020I1 (no)
CZ (2) CZ301375B6 (no)
DE (3) DE122008000065I1 (no)
DK (2) DK1109558T3 (no)
ES (2) ES2234302T3 (no)
FR (1) FR09C0001I2 (no)
GE (1) GEP20053420B (no)
HK (2) HK1040060A1 (no)
HU (2) HU224215B1 (no)
IL (6) IL141893A0 (no)
LU (1) LU91504I2 (no)
MX (2) MXPA01002598A (no)
NL (1) NL300371I2 (no)
NO (4) NO319434B1 (no)
NZ (2) NZ510384A (no)
PL (3) PL196668B1 (no)
PT (2) PT1096937E (no)
RU (2) RU2214233C2 (no)
SI (2) SI1096937T1 (no)
TR (2) TR200101261T2 (no)
TW (1) TWI241911B (no)
UA (2) UA67793C2 (no)
WO (2) WO2000013686A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CA2398691A1 (en) 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
EP1909767A2 (en) * 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20090091253A1 (en) * 2006-03-17 2009-04-09 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
AU2009212254A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
US20120177729A1 (en) * 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (no) 2011-07-01 2018-04-28
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ, インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
EP0719558B1 (en) * 1989-06-23 2002-06-05 Syntex (U.S.A.) LLC Ranolazine and related piperazines for use in the treatment of shock conditions
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
US20020004506A1 (en) 2002-01-10
NZ510386A (en) 2003-08-29
KR100475759B1 (ko) 2005-03-10
US20020090396A1 (en) 2002-07-11
EP1527779A1 (en) 2005-05-04
HUP0103844A3 (en) 2002-11-28
US20040029890A1 (en) 2004-02-12
CN1193757C (zh) 2005-03-23
HUP0103844A2 (hu) 2002-04-29
WO2000013686A3 (en) 2000-07-06
WO2000013687A3 (en) 2000-06-29
TR200101262T2 (tr) 2001-12-21
US20030099705A1 (en) 2003-05-29
HK1040060A1 (en) 2002-05-24
DK1096937T3 (da) 2005-05-09
ES2177346T3 (es) 2002-12-01
EP1096937B1 (en) 2004-12-29
US6369062B1 (en) 2002-04-09
US6864258B2 (en) 2005-03-08
AR053440A2 (es) 2007-05-09
AU2008207703A1 (en) 2008-09-25
US20050153982A1 (en) 2005-07-14
FR09C0001I2 (no) 2009-12-18
HK1044284B (zh) 2005-07-15
JP2006096757A (ja) 2006-04-13
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
ATE217794T1 (de) 2002-06-15
EP1096937A2 (en) 2001-05-09
US20050059667A1 (en) 2005-03-17
US6620814B2 (en) 2003-09-16
PT1109558E (pt) 2002-10-31
CA2343376A1 (en) 2000-03-16
ES2234302T3 (es) 2005-06-16
GEP20053420B (en) 2005-01-25
BR9913626A (pt) 2001-12-04
UA67793C2 (uk) 2004-07-15
BR9913553A (pt) 2001-10-23
US6303607B1 (en) 2001-10-16
CN1211086C (zh) 2005-07-20
JP3745621B2 (ja) 2006-02-15
US20030166659A1 (en) 2003-09-04
IL141892A (en) 2006-08-20
HU224215B1 (hu) 2005-06-28
PL348249A1 (en) 2002-05-20
WO2000013687A2 (en) 2000-03-16
NO20054324L (no) 2001-04-30
CN1321088A (zh) 2001-11-07
HUP0104088A3 (en) 2002-12-28
DE122008000065I1 (de) 2009-04-09
AU6142599A (en) 2000-03-27
IL141893A0 (en) 2002-03-10
CZ301375B6 (cs) 2010-02-03
DE69922964D1 (de) 2005-02-03
CY2008020I2 (el) 2010-07-28
EP1109558A2 (en) 2001-06-27
NL300371I1 (nl) 2009-02-02
IL141893A (en) 2008-08-07
US6852724B2 (en) 2005-02-08
PT1096937E (pt) 2005-04-29
DE69922964T2 (de) 2005-12-08
NO2009005I1 (no) 2009-03-16
SI1109558T1 (en) 2002-10-31
UA75027C2 (uk) 2006-03-15
NO20011191D0 (no) 2001-03-08
US20060217397A1 (en) 2006-09-28
PL196668B1 (pl) 2008-01-31
HK1044284A1 (en) 2002-10-18
NO20011192D0 (no) 2001-03-08
IL180864A0 (en) 2007-07-04
JP2002524416A (ja) 2002-08-06
NL300371I2 (nl) 2009-10-01
NO320986B1 (no) 2006-02-20
IL141892A0 (en) 2002-03-10
AR022085A1 (es) 2002-09-04
TR200101261T2 (tr) 2002-05-21
MXPA01002598A (es) 2002-04-08
MXPA01002599A (es) 2005-02-17
DE69901570D1 (de) 2002-06-27
NZ510384A (en) 2002-10-25
US20030100566A1 (en) 2003-05-29
LU91504I9 (no) 2019-01-02
SI1096937T1 (en) 2005-04-30
DK1109558T3 (da) 2002-08-26
KR20010089874A (ko) 2001-10-12
US20040097514A1 (en) 2004-05-20
US6617328B2 (en) 2003-09-09
AU744071B2 (en) 2002-02-14
CA2342390A1 (en) 2000-03-16
IL175371A0 (en) 2006-09-05
ATE285774T1 (de) 2005-01-15
US6562826B1 (en) 2003-05-13
CZ2001880A3 (cs) 2001-08-15
CA2342390C (en) 2006-08-29
LU91504I2 (fr) 2009-02-03
RU2207856C2 (ru) 2003-07-10
AU6036499A (en) 2000-03-27
DE69901570T2 (de) 2003-01-09
EP1096937B9 (en) 2007-02-28
CA2343376C (en) 2007-01-09
NO2009005I2 (no) 2010-06-28
FR09C0001I1 (no) 2009-02-27
AR052921A1 (es) 2007-04-11
AU760435B2 (en) 2003-05-15
TWI241911B (en) 2005-10-21
CY2008020I1 (el) 2010-07-28
PL196263B1 (pl) 2007-12-31
NO319434B1 (no) 2005-08-15
AU2008207707A1 (en) 2008-09-25
RU2214233C2 (ru) 2003-10-20
CZ301341B6 (cs) 2010-01-20
US20060147521A1 (en) 2006-07-06
CN1354665A (zh) 2002-06-19
CZ2001879A3 (cs) 2001-08-15
US6503911B2 (en) 2003-01-07
PL202207B1 (pl) 2009-06-30
NO20011191L (no) 2001-04-30
EP1109558B1 (en) 2002-05-22
HUP0104088A2 (hu) 2002-05-29
US6525057B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
NO20011192L (no) Ranolazinpreparater med depotvirkning
ID26162A (id) Turunan-turunan benzilbifenil biosida
DE69720461D1 (de) Epoxybinder enthaltender flächenreissverschluss
DE59901560D1 (de) Retrograder tibianagel
ID29885A (id) Penghambat serina protease
DE69913574D1 (de) Ferromagnetische Tunneleffektanordnung
DK0928790T3 (da) Thiazolderivater
DE69714146D1 (de) Polyether modifizierte Fluoralkylsiloxane
DE59706428D1 (de) Schaltungsanordnung
ATE246494T1 (de) Brausezubereitungen
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59807217D1 (de) Nadellager
DK1123283T3 (da) Thiazolderivater
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung
DE69911967D1 (de) Schleifkörper
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
DK0928793T3 (da) Thiazolderivater
FR2779343B1 (fr) Linceul
ATA126298A (de) Verpuffungsklappe
DE59900975D1 (de) Falzwalzenlagerung
ATA72498A (de) Konservierungssarkophag
FI980682A0 (fi) Foerfarande och anordning i en fiberbelaeggningslinje
SE9802189D0 (sv) New Proteins
FR2778665B1 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GILEAD SCIENCES, US

MK1K Patent expired